148274-88-8
Chemical Structure
OVA-T4 Peptide
Synonym(s): SIITFEKL, OVA (257-264) Variant
- CAS No.: 148274-88-8
- Formula:C45H75N9O13
- Molecular Weight:950.13
InChIKey: LHCVSOBJLZOLJV-RASQMKTFSA-N
SMILES: CC(C)C[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@H]([C@@H](C)CC)NC([C@H]([C@@H](C)CC)NC([C@@H](N)CO)=O)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O
Biological Activity: OVA-T4 Peptide (SIITFEKL; OVA (257-264) Variant) is a modified peptide ligand of OVA 257-264 that binds to mouse OT-I TCR with Kd = 1.22 μM, acts as a weaker agonist than the parental N4 peptide to modulate the strength of antigen-presenting cell-T lymphocyte interactions, and alters the amplitude of cytokine responses and NFAT1, p-Erk, and NF-κB signaling responses. OVA-T4 Peptide can be used for research on colon cancer and ovarian cancer[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
OVA-T4 Peptide | 99.59% | OVA-T4 Peptide (SIITFEKL; OVA (257-264) Variant) is a modified peptide ligand of OVA 257-264 that binds to mouse OT-I TCR with Kd = 1.22 μM, acts as a weaker agonist than the parental N4 peptide to modulate the strength of antigen-presenting cell-T lymphocyte interactions, and alters the amplitude of cytokine responses and NFAT1, p-Erk, and NF-κB signaling responses. OVA-T4 Peptide can be used for research on colon cancer and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Liu S, et al. PRECISE-seq reveals disease-relevant TCR repertoires with phenotypic plasticity. The Journal of experimental medicine. 2026 Jun 01;223(6):e20251779.
- [2]. Teagle, et al. The role of tyrosine phosphatase PTPN22 in CTL responses to tumours and T cell exhaustion. (2024).
- [3]. Brownlie RJ, et al. Deletion of PTPN22 improves effector and memory CD8+ T cell responses to tumors. JCI insight. 2019 Jul 23;5(16):e127847.
- [4]. Petkau G, et al. Zfp36l1 establishes the high-affinity CD8 T-cell response by directly linking TCR affinity to cytokine sensing. European journal of immunology. 2024 Feb;54(2):e2350700. [Content Brief]
- [5]. Salerno F, et al. Distinct PKC-mediated posttranscriptional events set cytokine production kinetics in CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America. 2017 Sep 05;114(36):9677-9682.
- [6]. Gallagher MP, et al. The Tec kinase ITK differentially optimizes NFAT, NF-κB, and MAPK signaling during early T cell activation to regulate graded gene induction. bioRxiv. 2020 Nov 14:2020-11.
- [7]. Gregory M, et al. Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma. Journal for immunotherapy of cancer. 2026 Mar 27;14(3):e014080.
